title: Nitric oxide inhibits leucocyte migration in carrageenin-induced rat pleurisy.
abstract: OBJECTIVE
  The role of nitric oxide (NO) on leucocyte migration has been investigated in rat carrageenin-induced pleurisy.
  
  
  METHODS
  Male Wistar rats.
  
  
  METHODS
  L-arginine, NOC-18 and aminoguanidine were administered subcutaneously 1 h prior to carrageenin injection.
  
  
  METHODS
  Leucocyte accumulation into the pleural cavity was measured 4 h after carrageenin challenge. Statistical significance was calculated by Bonferroni test.
  
  
  RESULTS
  L-arginine (10 mg/kg) or the NO donor NOC-18 (10 mg/kg), significantly inhibited leucocyte infiltration by 31% and 20% respectively (P<0.01). On the contrary, when these compounds were given at high doses (L-arginine 300 mg/kg; NOC-18 30 mg/kg), leucocyte accumulation was increased by 22% and 33% respectively (P<0.01). Aminoguanidine, a relatively selective inhibitor of the inducible NO synthase, depending on the dose, showed a biphasic effect on cell migration. Thus, at low doses (30 and 100 mg/kg), aminoguanidine increased (by 40% and 74% respectively, P< 0.01) leucocyte infiltration which was inhibited by 41% (P < 0.01) when the drug was given at high dose (300 mg/kg).
  
  
  CONCLUSIONS
  These results suggest that in rat carrageenin-induced pleurisy NO primarily inhibits leucocyte migration.
authors.affiliation: Department of Experimental Pharmacology, University of Naples Federico II, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ialenti
authors.forename: A
authors.initials: A
authors.lastname: Ianaro
authors.forename: P
authors.initials: P
authors.lastname: Maffia
authors.forename: L
authors.initials: L
authors.lastname: Sautebin
authors.forename: M
authors.initials: M
authors.lastname: Di Rosa
mesh_terms: D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000494:pharmacology; D001794:Blood Pressure; D002351:Carrageenan; D002465:Cell Movement / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology; D007962:Leukocytes / Q000502:physiology*; D008297:Male; D009569:Nitric Oxide / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000008:administration & dosage / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D052247:Nitric Oxide Synthase Type II; D009603:Nitroso Compounds / Q000008:administration & dosage / Q000494:pharmacology; D010994:Pleura / Q000473:pathology; D010996:Pleural Effusion / Q000473:pathology / Q000503:physiopathology; D010998:Pleurisy / Q000139:chemically induced / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D004791:Enzyme Inhibitors; D006146:Guanidines; C093285:NOC 18; D020030:Nitric Oxide Donors; D009603:Nitroso Compounds; D009569:Nitric Oxide; D002351:Carrageenan; D001120:Arginine; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; C004479:pimagedine